Clinical variability in neuromyelitis optica: Three case reports;Variabilidad clínica en la neuromielitis óptica: Descripción de tres casos

Revista de Neurologia

Volumn 52, Issue 3, 2011, Pages 154-158

  Ayuga Loro, Fernando ^a   Teijeira Azcona, Ana ^b  

^a HOSPITAL NACIONAL DE PARAPLÉJICOS   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

Author keywords

Differential diagnosis; Multiple sclerosis; Neuromyelitis optica; NMO antibodies; Transverse myelitis

Indexed keywords

ANTIBODY; AUTOANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CASE REPORT; EVOKED VISUAL RESPONSE; FEMALE; HUMAN; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY;

ADOLESCENT; AGED; AUTOANTIBODIES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MYELITIS, TRANSVERSE; NEUROMYELITIS OPTICA;

EID: 79952233528     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5203.2010454     Document Type: Article

References (14)

1. Wingerchuk DM, Hogacamp WF, O'Brian PC, Wheishenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53: 1107-14. (Pubitemid 29442132)
2. Devic E. Myélite subaigüe compliquée de neurite optique. Bull Med 1894; 8: 1033-4.
3. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-9. (Pubitemid 43958540)
4. Saiz A, Zuliani L, Blanco Y, Tavolato B, Giometto B, Graus F. Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol 2007; 254: 1233-7. (Pubitemid 350112363)
5. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock ST, Lucchinetti CF, Fujihara K. A serum antibody marker optic neuromyelitis. Distinction from multiple sclerosis. Lancet 2004; 364: 2106-12.
6. Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006; 59: 566-9. (Pubitemid 43358081)
7. Blanco Y, Hankiewicz K, Llufriu S, Sabater L, Graus F, Saiz A. Clinical spectrum associated with aquaporin-4 antibodies (NMO-IgG). Neurologia 2010; 25: 5-12.
8. Yanagawa K, Kawachi I, Toyoshima Y, Yockoseki A, Arakawa M, Hasegawa A, et al. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology 2009; 73: 1628-37.
9. Lopategui-Cabezas I, Cervantes-Llano M, Pentón-Rol G. Neuromielitis óptica. Principales diferencias con la esclerosis múltiple. An Med Interna (Madrid) 2008; 25: 294-6.
10. Chiquete E, Navarro-Bonnet J, Ayala-Armas R, Gutiérrez- Gutiérrez N, Solórzano-Meléndez A, Rodríguez-Tapia D, et al. Neuromielitis óptica: actualización clínica. Rev Neurol 2010; 51: 289-94.
11. Sebastián de la Cruz F, López-Dolado E. Neuromielitis óptica de Devic: análisis de siete casos. Rev Neurol 1999; 28: 476-82.
12. Masuhr F, Busch M, Wetzel K, Harms L, Schielke E. Relapsing myelitis with pathological visual evoked potentials: a case of neuromyelitis optica? Eur J Neurol 2002; 9: 430-2.
13. Tanaka M, Tanaka K, Komori M. Interferon-beta(1b) treatment in neuromyelitis optica. Eur Neurol 2009; 62: 167-70.
14. Cree B, Lamb S, Chin A, Bonovich D, Islar J, Waubant E, et al. Tolerability and effects of rituximab (anti-CD20 antibody) in neuromyelitis optica (NMO) and rapidly worsening multiple sclerosis (MS). Neurology 2004; 62 (Suppl 5): S492.